COVID-19 Treatment

Yanavir 

A PRODUCT FOR THE TREATMENT OF COVID-19 AND LONG COVID


The vaccines are here, but we still need a treatment for Covid-19 and Long Covid

  • Vaccines are not 100% effective
  • New variants are emerging
  • Post-Covid syndrome or ‘Long Covid’ also needs a treatment


Indigena Biodiversity Limited has a development opportunity, ready for licensing, which is an ideal complement to vaccines. Already having clinical data, it provides an antiviral agent with proven efficacy, not only against Covid -19 but also against Long Covid. The ingredients are safe natural products.


Natural products

Natural products, including plant species, provide a huge diversity of chemical complexity. Many pharmaceutical products on the market today are based on compounds isolated from a natural source.


The present product

Our approach is based on nicotine as a cholinergic agonist, derived from specific varieties of medicinal tobacco, and combined with other natural products that act synergistically to modulate and enhance the effects of tobacco alkaloids. Appropriate routes of administration are also important.


The result is an antiviral agent that provides both prophylaxis and treatment by:

  • Reinforcing the natural immunity disrupted by SARS-CoV-2. Thus, entry of the virus is prevented, or its viral load decreased.
  • Regulating the cholinergic pathway by stimulation of the nicotinic acetylcholine receptor (nAChR)

   

The unique combination of activities offers an opportunity for a rapid development, low cost, easy storage, product for prevention and treatment of Covid-19 and Long Covid, exhibiting good tolerance and safety. It is a candidate for either an over-the-counter product or a pharmaceutical product under oral, nasal and/or nebulized administration.


There are two forms of the product:

  • A phytotherapeutic product that contains up to 22 active principles from 5 natural plant species
  • A pharmaceutical preparation that can contain from 3 up to 6 or more individual chemical compounds



Preliminary evidence

A compassionate use trial on a small group of Covid-19 patients has showed remarkable results. Symptoms were reduced significantly within 4 hours. After 24 hours, symptoms were so diminished that disease could be considered to be reversed. After 72 hours patients felt well, with few or no symptoms of the disease. No relapses have been observed. Further clinical trials are underway.

 

Statistically significant reduction of the following symptoms of Long Covid have been demonstrated:

  • Dyspnea (shortness of breath)
  • Cough
  • Cephalea (headache)
  • Muscular fatigue
  • General malaise


These findings are encouraging because dyspnea, cough, and fatigue are highly prevalent and strongly linked with severe disease, hospitalization and death.


Is nicotine carcinogenic or addictive?

The toxic effects caused by cigarette smoking are not primarily due to nicotine, but instead the carcinogens and other toxins produced by the burning of tobacco and inhalation of the smoke. Nicotine itself is neither carcinogenic nor significantly addictive. The Royal Society for Public Health UK has stated that 'Nicotine is no more harmful to health than caffeine'.

 

Intellectual property

Two  families of patent applications  have been filed in internationally, which separately protect the phytotherapeutic product and pharmaceutical preparation.

 

The originators

Indigena Biodiversity represents a Colombian company called Niccovid - group of medical doctors, chemists, molecular biologists, ethnobotanical specialists from Spain, Italy, France, Colombia, Argentina and Peru. The operations centre is based in Colombia. The team has of over 15 years’ experience in the field of administering cholinergic agonists for several various pathologies and an extensive knowledge of tobacco and many other plants.

 

Further information is available

We are seeking a company to develop and market this antiviral treatment for Covid-19 and Long Covid, taking a licence under the patents. We have named the product Yanavir. A licensee may choose that name or a different name.


To enquire about this opportunity, please quote our reference CO 54

Contact
Share by: